

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Suzhou Basecare Medical Corporation Limited

蘇州貝康醫療股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2170)

CHANGE IN EXECUTIVE DIRECTOR

Reference is made to the announcement of Suzhou Basecare Medical Corporation Limited (the “**Company**”) dated March 30, 2022 and the circular of the Company dated April 7, 2022 (the “**Circular**”) in relation to the resignation of Mr. RUI Maoshe (“**Mr. Rui**”) as an executive director of the Company (an “**Executive Director**”) and the proposed appointment of Ms. YANG Ying (“**Ms. Yang**”) as an Executive Director.

CHANGE IN EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that resolution regarding the appointment of Ms. Yang as an Executive Director was approved at the extraordinary general meeting of the Company (the “**EGM**”) held on April 30, 2022. The appointment of Ms. Yang as an Executive Director has become effective on the date of the EGM, being April 30, 2022. Poll results of the EGM are set out in the poll results announcement of the Company dated April 30, 2022.

The biographical details and other relevant information regarding Ms. Yang are set out in the Circular. As of the date of this announcement, there has been no change to such information save as otherwise disclosed in this announcement.

The Company has entered into a letter of appointment with Ms. Yang in relation to her appointment as an Executive Director for a term commencing from the date of approval of her appointment at the EGM, being April 30, 2022, and expiring on the conclusion of the first session of the Board of Directors. This term of office is terminable by either party serving on the other not less than three months’ written notice, and subject to retirement and re-election in accordance with the articles of association of the Company and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). Ms. Yang will not receive any director’s fee or remuneration for serving as an executive Director from the Company. The remuneration of Ms. Yang will be subject to review by the Board and the Remuneration and Appraisal Committee from time to time.

Save as disclosed above, there is no other matter concerning Ms. Yang's appointment or Mr. Rui's resignation that need to be brought to the attention of the shareholders of the Company.

By Order of the Board
Suzhou Basecare Medical Corporation Limited
Dr. Liang Bo
Chairman and General Manager

Suzhou, PRC, May 2, 2022

As of the date of this announcement, the Board comprises Dr. LIANG Bo, Mr. KONG Lingyin and Ms. YANG Ying as executive Directors; Mr. XU Wenbo, Mr. ZHANG Jiecheng and Mr. WANG Weipeng as non-executive Directors; and Dr. KANG Xixiong, Dr. HUANG Taosheng and Mr. CHAU Kwok Keung as independent non-executive Directors.